Sonoma Pharmaceuticals Inc
NASDAQ:SNOA
Sonoma Pharmaceuticals Inc
Capital Expenditures
Sonoma Pharmaceuticals Inc
Capital Expenditures Peer Comparison
Competitive Capital Expenditures Analysis
Latest Figures & CAGR of Competitors
Company | Capital Expenditures | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Sonoma Pharmaceuticals Inc
NASDAQ:SNOA
|
Capital Expenditures
-$210k
|
CAGR 3-Years
10%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
10%
|
|
Johnson & Johnson
NYSE:JNJ
|
Capital Expenditures
-$4.5B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-2%
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Capital Expenditures
-$1.2B
|
CAGR 3-Years
-18%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-8%
|
|
Pfizer Inc
NYSE:PFE
|
Capital Expenditures
-$3.5B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-9%
|
|
Merck & Co Inc
NYSE:MRK
|
Capital Expenditures
-$3.7B
|
CAGR 3-Years
7%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-10%
|
|
Eli Lilly and Co
NYSE:LLY
|
Capital Expenditures
-$7.6B
|
CAGR 3-Years
-50%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
-21%
|
See Also
What is Sonoma Pharmaceuticals Inc's Capital Expenditures?
Capital Expenditures
-210k
USD
Based on the financial report for Dec 31, 2023, Sonoma Pharmaceuticals Inc's Capital Expenditures amounts to -210k USD.
What is Sonoma Pharmaceuticals Inc's Capital Expenditures growth rate?
Capital Expenditures CAGR 10Y
10%
Over the last year, the Capital Expenditures growth was -50%. The average annual Capital Expenditures growth rates for Sonoma Pharmaceuticals Inc have been 10% over the past three years , -16% over the past five years , and 10% over the past ten years .